In a clinical study on estrogen-receptor-positive primary breast cancer patients, hormonal therapy failure in [18F]FES negative cases was investigated [77]: [18F]FES sensitivity and specificity for detection of ER positive lesions was estimated at 84% to 94% for breast cancer and 79% to 100% for ovarian cancer, respectively [53]. This evidence concerns the gene ESR1 and ovarian carcinoma.